Want to see CH:GIVN full AI Analyst Report?
Top Page
Givaudan SA
(GIVN)
Select Model
Select Model
Rating:70Outperform
Price Target:
CHF3,762.00
▲(26.92% Upside)
Action:Reiterated
Date:02/08/26
The score is driven primarily by strong financial quality (durable margins, solid ROE, and consistent free cash flow) and a supportive earnings outlook/strategy execution. These positives are tempered by weak technical momentum (price below key moving averages with negative MACD) and a relatively high P/E, with leverage remaining the main fundamental risk factor.
Positive Factors
Consistent Free Cash Flow
Sustained, multi-year free cash flow above CHF 1bn demonstrates durable cash generation that funds dividends, buybacks, M&A and R&D without reliance on equity raises. This strengthens long-term financial flexibility and supports capital allocation through business cycles.
Negative Factors
Meaningful Leverage
Elevated leverage increases sensitivity to interest rates and cyclical downturns, limiting financial flexibility for large capex or acquisitions. Even with improvement, coverage ratios and reliance on operating cash make the capital structure more vulnerable to margin or revenue shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Free Cash Flow
Sustained, multi-year free cash flow above CHF 1bn demonstrates durable cash generation that funds dividends, buybacks, M&A and R&D without reliance on equity raises. This strengthens long-term financial flexibility and supports capital allocation through business cycles.
Read all positive factors
Givaudan SA (GIVN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF31.56B
Dividend Yield2.24%
Average Volume (3M)20.82K
Price to Earnings (P/E)29.6
Beta (1Y)0.81
Revenue Growth0.81%
EPS Growth-1.77%
CountryCH
Employees16,942
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)115.51
Shares Outstanding9,233,586
10 Day Avg. Volume25,269
30 Day Avg. Volume20,823
Financial Highlights & Ratios
PEG Ratio-11.97
Price to Book (P/B)6.43
Price to Sales (P/S)3.90
P/FCF Ratio24.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF3,248.75Price Target Upside9.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)120.66
Revenue Forecast (FY)CHF7.58B
Givaudan SA Business Overview & Revenue Model
Company Description
Founded in Vernier, Switzerland in 1796, Givaudan SA is a global leader specializing in the development, production, and supply of fragrance, beauty, taste, and wellbeing solutions for the consumer goods industry. The company operates through two ...
How the Company Makes Money
Givaudan makes money primarily by selling formulated products and ingredients to business customers, with revenue largely generated from long-term supply relationships with consumer goods companies and from project-based product development for br...
Givaudan SA Earnings Call Summary
Earnings Call Date:Jan 29, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 23, 2026
Earnings Call Sentiment Positive
The call presented a broadly positive picture: Givaudan delivered solid like-for-like sales growth (5.1%), strong free cash flow (>CHF 1 billion), continued outperformance in Fragrance & Beauty (Fine Fragrances +18.3%) and successful delivery of the 2021–2025 strategic cycle with meaningful ESG and R&D milestones. Headwinds included modest margin compression (gross margin -0.6 ppt), localized weaknesses in Fragrance Ingredients and parts of Taste & Wellbeing (Mexico, some APAC markets), FX impacts from a strong Swiss franc, nonrecurring costs and tariff-related uncertainty. Overall, the strengths — healthy organic growth, robust cash generation, improved leverage and proven strategy execution — materially outweigh the manageable challenges reported.Positive Updates
Strong Group Sales Growth
Group sales of CHF 7.472 billion in 2025, up 5.1% like-for-like (LFL) and +0.8% in Swiss francs versus prior year; growth achieved across markets and customer segments.
Negative Updates
Slight Compression of Gross and EBITDA Margins
Gross margin decreased from 44.1% to 43.5% in 2025; comparable EBITDA margin declined to 24.2% from 24.5% in 2024, reflecting higher input costs, tariffs and competitive pressures in parts of the portfolio.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Group Sales Growth
Group sales of CHF 7.472 billion in 2025, up 5.1% like-for-like (LFL) and +0.8% in Swiss francs versus prior year; growth achieved across markets and customer segments.
Read all positive updates
Company Guidance
The company guided into a new 2026 year and 2030 strategic cycle targeting average like‑for‑like sales growth of 4–6% and maintaining industry‑leading free cash flow above 12% of sales by 2030, while for 2026 management expects continued momentum in Fragrance & Beauty, a temporary Taste & Wellbeing slowdown easing through H2 (a ~2–3 point H1/H2 split), only limited input‑cost inflation, uncertain tariff effects to be managed via pricing, and some ongoing nonrecurring costs; this outlook sits on a 2025 base of CHF 7.472bn sales (+5.1% LFL), comparable EBITDA margin 24.2%, net income CHF 1,071m (14.3% margin), free cash flow CHF 1,053m (14.1%), and net debt/EBITDA of 2.1x, with a proposed dividend of CHF 72 (+2.9%).Givaudan SA Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
71
Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.47B | 7.41B | 6.92B | 7.12B | 6.68B |
| Gross Profit | 3.25B | 3.27B | 2.72B | 2.63B | 2.70B |
| EBITDA | 1.79B | 1.79B | 1.47B | 1.38B | 1.44B |
| Net Income | 1.07B | 1.09B | 893.00M | 856.00M | 821.00M |
Balance Sheet | |||||
| Total Assets | 11.86B | 12.10B | 11.13B | 11.51B | 11.43B |
| Cash, Cash Equivalents and Short-Term Investments | 742.00M | 762.00M | 608.00M | 488.00M | 278.00M |
| Total Debt | 4.42B | 4.75B | 4.91B | 5.00B | 4.67B |
| Total Liabilities | 7.30B | 7.52B | 7.13B | 7.27B | 7.49B |
| Stockholders Equity | 4.54B | 4.58B | 3.99B | 4.23B | 3.93B |
Cash Flow | |||||
| Free Cash Flow | 1.21B | 1.33B | 1.10B | 588.00M | 969.00M |
| Operating Cash Flow | 1.51B | 1.63B | 1.37B | 892.00M | 1.23B |
| Investing Cash Flow | -380.00M | -448.00M | -467.00M | -451.00M | -921.00M |
| Financing Cash Flow | -1.11B | -1.03B | -699.00M | -229.00M | -440.00M |
Givaudan SA Technical Analysis
Positive
2964.00
Price Trends
2940.32
Positive
2886.11
Positive
3043.29
Positive
Market Momentum
135.52
Negative
78.98
Negative
88.70
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:GIVN, the sentiment is Positive. The current price of 2964 is below the 20-day moving average (MA) of 3124.65, above the 50-day MA of 2940.32, and below the 200-day MA of 3043.29, indicating a bullish trend. The MACD of 135.52 indicates Negative momentum. The RSI at 78.98 is Negative, neither overbought nor oversold. The STOCH value of 88.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:GIVN.
Givaudan SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | CHF16.21B | 34.70 | 22.08% | 3.16% | -5.85% | 1.24% | |
70 Outperform | CHF31.56B | 29.61 | ― | 2.24% | 0.81% | -1.77% | |
69 Neutral | CHF26.76B | 25.61 | ― | 2.23% | -4.78% | -16.18% | |
63 Neutral | CHF21.66B | 29.22 | ― | 1.29% | 8.18% | 8.38% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | CHF2.32B | -30.53 | 5.38% | 5.97% | -5.71% | -130.75% | |
51 Neutral | CHF6.14B | 25.28 | ― | 2.31% | 9.39% | 68.92% |
* General Sector Average
CH:GIVN
Givaudan SA
3,420.00
-353.74
-9.37%
CH:SIKA
Sika AG
166.75
-41.41
-19.89%
CH:LISN
Chocoladefabriken Lindt & Spruengli AG
96,000.00
-34,172.70
-26.25%
CH:BARN
Barry Callebaut AG
1,121.00
241.23
27.42%
CH:CLN
Clariant AG
7.05
-0.97
-12.06%
CH:EMSN
EMS-CHEMIE HOLDING AG
693.00
108.76
18.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.